Daktarin 2% w/w Cream
- Name:
Daktarin 2% w/w Cream
- Company:
Johnson & Johnson (Ireland) Ltd
- Active Ingredients:
- Legal Category:
Supply through pharmacy only
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 23/07/20
(Click to Download)Click on this link to Download PDF directly
Johnson & Johnson (Ireland) Ltd
 Ltd.jpg)
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 23 July 2020 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 5 - how to store or dispose
- Change to section 6 - date of revision
Updated on 17 June 2019 SmPC
Reasons for updating
- File format updated to PDF
Legal category: Supply through pharmacy only
Updated on 25 January 2018 PIL
Reasons for updating
- New PIL for new product
Updated on 25 January 2018 PIL
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 23 January 2018 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Supply through pharmacy only
Updated on 23 January 2018 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
|
PA Transfer from McNeil Healthcare (Ireland) Ltd to Johnson & Johnson (Ireland) Ltd. Change in PA number. Note the address and contact details remain the same. |
Updated on 19 January 2016 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Section 4.8
Angioedema moved from SOC "Immune System Disorders" to Skin and "subcutaneous Tissue Disorders"
Updated on 19 November 2015 SmPC
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Section 4.3 - Addition of the underlined text:
Hypersensitivity to the active substance, other imidazole derivatives or to any of the excipients listed in section 6.1.Section 4.4 - addition of the following text
Severe hypersensitivity reactions, including anaphylaxis and angioedema, have been reported during treatment with miconazole topical formulations. If a reaction suggesting hypersensitivity or irritation should occur, the treatment should be discontinued. Daktarin Cream must not come into contact with the mucosa of the eyes.
Section 4.8 - Additional of adverse event reporting details
(Miconazole PRAC updates, SNAS 1409)
Updated on 18 November 2015 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change of contraindications
Updated on 24 June 2014 SmPC
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 16 October 2013 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 15 October 2013 PIL
Reasons for updating
- Change to dosage and administration
Updated on 18 April 2013 PIL
Reasons for updating
- Change due to user-testing of patient information
Updated on 19 October 2011 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.1 - List of excipients
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
In Section 4.4, the following excipient warning has been added:
Benzoic acid (E210) can mildly irritate the skin, eyes and mucosal membranes.
Butylated hydroxyanisole (E320) may cause local skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucosa membranes.
In Section 6.1, the Macrogol content has been clarified:
Macrogol 6 (PEG 6)
Macrogol 32 (PEG 32)
Updated on 12 August 2010 PIL
Reasons for updating
- Change of manufacturer
Updated on 29 October 2009 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - MA number
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 23 October 2009 PIL
Reasons for updating
- Change to MA holder contact details
Updated on 13 May 2009 SmPC
Reasons for updating
- Change to section 10 - Date of revision of the text
- Change to section 6.1 - List of excipients
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 9 - Date of renewal of authorisation
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
|
1. |
NAME OF THE MEDICINAL PRODUCT |
Changed to Daktarin 2% w/w Cream
|
|
2. |
QUALITATIVE AND QUANTITATIVE COMPOSITION |
Addition of : Excipients; contains 0.2% w/w benzoic acid (E210) and 0.005% w/w butylated hydroxyanisole (E320)
Addition of Full statement added: For a full list excipients, see section 6.1. |
|
6.1 |
List of excipients |
Name change: unsaturated polyglycolysed glycerides to oleoylmacroglycerides |
|
9. |
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION |
Renewal of product licence 31 March 2008 |
|
10. |
DATE OF REVISION OF THE TEXT |
Changed to May 2009
|
Updated on 11 May 2009 PIL
Reasons for updating
- Change of trade or active ingredient name
- Change to date of revision
Updated on 19 January 2009 PIL
Reasons for updating
- PIL re-instated
Updated on 19 January 2009 PIL
Reasons for updating
- Change to side-effects
- Change to drug interactions
- Change to date of revision
Updated on 20 March 2006 PIL
Reasons for updating
- Change to drug interactions
- Change to side-effects
Updated on 20 March 2006 SmPC
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Updated on 17 May 2005 SmPC
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.2 - Posology and method of administration
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 10 - Date of revision of the text
- Change to section 9 - Date of renewal of authorisation
Legal category: Supply through pharmacy only
Updated on 31 March 2005 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 5 June 2003 SmPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Supply through pharmacy only